Diasorin is negotiating a strategic partnership with a global healthcare giant and the selection should be completed by the end of this year or early next. The company that operates in diagnostics records a 1,71% share on the Stock Exchange even if the accounts were slightly lower than analysts' expectations.
It was the managing director of the company, Carlo Rosa, who anticipated the news during the presentation of the results for the second quarter. Rosa explained that, given the growing pressures on healthcare systems to contain costs, large laboratories often turn to the giants of the sector for a complete range of tests. As a result, healthcare companies are looking for strategic partners to cover specific segments of diagnostics and Diasorin offers itself as a partner.
Diasorin closed the second quarter of the year with revenues down to 113,9 million (-1%), an ebitda at 42,3 million (-5,5%), an ebit also down to 35,4 million (37,6 million in 2012) and a net profit of 20,5 million (-11,1%) which was particularly affected by the increase in the tax rate and negative exchange rate fluctuations. Bloomberg analysts forecast slightly higher revenues for the period at 115 million euros, an ebitda of 44,8 million, an ebit of 37 million and a net profit of 24 million.
